Canagliflozin
Invokana / SGLT2 inhibitor
Canagliflozin (Invokana / SGLT2 inhibitor) is a longevity & bioregulators research compound. Blocks the sodium-glucose cotransporter in the proximal tubule so glucose is excreted in urine rather than reabsorbed. Beyond glucose, the class produces genuine cardiovascular and renal outcome benefits that appear largely independent of the glucose lowering.
Canagliflozin quick facts
| Reported research dose | 100mg-300mg |
| Route | Oral |
| Frequency | 1x Daily |
| Half-life | ~11-13 hrs |
| Forms | Oral |
| Evidence level | Strong human outcome trials; rodent lifespan data (males) |
Real cardiovascular and kidney outcome data — this class is one of the genuine advances of the last decade, and it also extended lifespan in male mice in the ITP. Watch for genital mycotic infections (common, mechanistically obvious — you're excreting sugar), volume depletion, and rarely euglycemic DKA, which is ketoacidosis with a NORMAL glucose and therefore easy to miss. Prescription only.
How Canagliflozin works
Blocks the sodium-glucose cotransporter in the proximal tubule so glucose is excreted in urine rather than reabsorbed. Beyond glucose, the class produces genuine cardiovascular and renal outcome benefits that appear largely independent of the glucose lowering.
Proposed benefits
Researched for mitochondrial and cellular-energy support, tissue-specific bioregulation and healthy-aging pathways.
Can you actually get Canagliflozin?
An SGLT2 inhibitor for type-2 diabetes. Needs a prescriber managing the diabetes, and none of my partners dispense it.
The evidence for Canagliflozin
Graded by what exists behind each claim.
✅ Clinically validated
- Approved for type 2 diabetes with major outcome trials behind it. CANVAS showed reduced major adverse cardiovascular events, and CREDENCE showed a significant reduction in kidney disease progression — a hard renal endpoint that changed practice.
- CANVAS also found roughly a doubling of amputation risk, which led to a boxed warning that was later removed after further data. The signal was real in that trial and did not replicate; both facts belong in the record.
- It also extended lifespan in male mice in the NIA Interventions Testing Program — again male-only, like acarbose and 17-alpha-estradiol.
📊 Correlative data
- Wide prescribing. The consistently reported issues are genital mycotic infections — a direct consequence of putting sugar in the urine — and volume depletion. Euglycemic diabetic ketoacidosis is rare, serious, and easy to miss because blood glucose looks normal.
🧪 Theoretical / extrapolated
- Inhibits SGLT2 in the proximal tubule, blocking glucose reabsorption so roughly 80 grams a day is excreted in urine. That is a genuinely novel mechanism — it lowers glucose independently of insulin entirely.
- The cardiovascular and renal benefits are larger than glucose-lowering explains, and are thought to come from reduced intraglomerular pressure, a shift toward ketone metabolism in the heart, and plasma volume reduction.
- Losing 80 g of glucose daily is roughly 300 calories out, which is the mechanism behind the modest weight loss — and also behind the caution that it is not a weight drug and carries real infection and DKA risk.
How to read these tiers: they say how much human evidence exists, not how well something works — and ✗ flags harm, never a disappointing trial. How the evidence tiers work →
What Canagliflozin actually does
Canagliflozin blocks a transporter, and the transporter is in the kidney rather than anywhere metabolically interesting. Everything else this drug does is downstream of throwing sugar away. Sodium-glucose cotransporter 2 sits on the apical membrane of the early proximal tubule and reabsorbs roughly 90% of filtered glucose, using the sodium gradient that the basolateral sodium-potassium ATPase maintains. Inhibit it and the reabsorptive threshold falls, so glucose that would have been recovered leaves in the urine.
The number that matters for a non-diabetic reader, and it is never stated. Filtered glucose load is glomerular filtration rate multiplied by plasma glucose. In someone with a fasting glucose of 10 mmol/L the filtered load is large and an SGLT2 inhibitor can excrete on the order of 80–100 g of glucose a day. In someone with a normal fasting glucose the filtered load is roughly half that, and the fraction the drug can capture is smaller still, because as plasma glucose falls the drug is working further down its own dose-response. The caloric-loss argument scales with your glycemia. The genital mycotic infection risk does not scale down with it, because that is driven by glucose in the urine, which is present either way. That asymmetry is the single most useful thing this page can tell a metabolically healthy reader.
The sodium half is why the cardiovascular effect is not a glucose effect. SGLT2 moves sodium as well as glucose, so inhibiting it raises sodium delivery to the macula densa, which restores tubuloglomerular feedback, constricts the afferent arteriole and lowers intraglomerular pressure. That produces the characteristic early dip in estimated GFR that then stabilizes, and it is a hemodynamic effect on the kidney rather than a metabolic one. It is also why the class's renal and heart-failure benefits appear in people without diabetes Sharma 2024 Chen 2024.
And a mild diuresis with an erythropoietic signal. Osmotic diuresis contracts plasma volume, which raises hematocrit; there is also evidence the class stimulates erythropoiesis directly by relieving hypoxic stress in the renal cortex. Either way the hematocrit rise is real, expected, and one of the few changes a reader will actually see on a routine panel.
Cell, rodent, human — and where it stops
Step one, humans, and it is the strong end. This is one of the few compounds in the Vault where the outcome trials came before the mechanism was fully understood. The CANVAS program and CREDENCE produced cardiovascular and kidney outcome results for canagliflozin specifically, and their primary outcomes and clinical implications have been summarized for practizing clinicians Chen 2024; a pooled analysis separated the primary-prevention population from the secondary-prevention one Sharma 2024. Nothing about the cardiorenal case is extrapolated.
Step two, the longevity claim — and here the page has to be exact, because the way this is repeated online is not what the data says. In genetically heterogeneous UM-HET3 mice, canagliflozin increased median lifespan by 14% and the 90th-percentile age by 9% in males. The pathology followed the same pattern: diminished cardiomyopathy, glomerulonephropathy, arteriosclerosis, hepatic lipidosis and adrenal cortical neoplasms in males only, with protection against pancreatic atrophy in both sexes Snyder 2023. The sex disparity was striking enough to prompt a commentary titled “Sex Matters in Aging” which notes the drug robustly retarded age-related lesions in male mice and less so in females, with no mechanistic explanation established Wezeman 2022. The longevity argument for this drug rests on one sex of one mouse stock, and half the readers of this page are not in it.
Step three, the obstacle. There is no human lifespan or healthspan trial of canagliflozin, and there will not be one soon. What exists is a hard cardiorenal outcome dataset in people with diabetes or kidney disease, and a rodent lifespan dataset with an unexplained sex split. Bridging those two into “take this for longevity if you are metabolically healthy” crosses a species, a disease state and a sex boundary all at once, and every one of those crossings is where the data actually stops.
Canagliflozin pharmacokinetics — how much of it actually gets in
The card says ~11–13 hours, which is right for the plasma curve and wrong as a guide to how long the drug is working.
What clears it, and it is unusual for a drug of this class. Canagliflozin is eliminated overwhelmingly by O-glucuronidation — principally by UGT1A9 and UGT2B4 — with only a minor contribution from cytochrome P450 oxidation and very little unchanged renal clearance of the parent. That matters practically: a drug cleared by glucuronidation has a different interaction profile from one cleared by CYP3A4, and the relevant interactions are with UGT inducers such as rifampicin and certain antiepileptics rather than with the usual CYP3A4 list. Genetic variation in these enzymes is part of why response to the class varies between people Klen 2021, and physiologically based models have been built to predict exposure and glucose-lowering across degrees of renal insufficiency Guo 2025.
The oral barrier, and why food timing is not neutral. Oral bioavailability is high — roughly two thirds — and first-pass metabolism is modest. The reason the dose is taken before the first meal is not absorption; it is that at the 300 mg dose canagliflozin also transiently inhibits intestinal SGLT1, blunting the post-meal glucose rise, and that effect only occurs if the drug is in the gut lumen when the food arrives. The same milligrams taken at bedtime are a different pharmacology.
The number that matters is not the half-life. The plasma half-life is 11–13 hours, but the pharmacodynamic effect — urinary glucose excretion — persists well beyond the plasma curve, because what is being inhibited is a transporter on a membrane and recovery depends on transporter turnover and on the filtered load. The drug is a once-daily drug because of the transporter, not because of the plasma level, and the effect on the kidney's glucose threshold outlasts the exposure that caused it.
The comparator, for completeness. No injectable form exists and none is needed; a small oral molecule with two-thirds bioavailability and a tubular target has no delivery problem to solve. Renal impairment reduces efficacy rather than raising exposure dangerously, because a lower filtration rate means less filtered glucose for the drug to act on Guo 2025 — which is the opposite of the usual renal-dosing intuition and is worth stating plainly.
What would have to be true, and how you would know it was not
Three predictions with markers, directions and windows. The third is the one that argues against using this outside its evidence base.
1. Hematocrit should rise, and if it does not the drug is not working. Osmotic diuresis contracts plasma volume and the class also appears to stimulate erythropoiesis. Order a CBC at baseline and at 12 weeks. Prediction: a modest, real rise in hematocrit and hemoglobin. That makes the CBC the cheapest confirmation that the drug is engaged — and it is also the measurement that tells anyone already running a high hematocrit for any other reason that this compound pushes the same number the same way.
2. Estimated GFR should DIP and then stabilize, and mistaking the dip for harm is the commonest error with this class. The dip is restored tubuloglomerular feedback lowering intraglomerular pressure — the mechanism behind the long-term kidney protection seen in CREDENCE Chen 2024. Order cystatin C with eGFR alongside a CMP at baseline, 4 weeks and 12 weeks. Prediction: a fall at 4 weeks, a plateau by 12, and no progressive decline. Cystatin C rather than creatinine alone, because creatinine tracks muscle mass and this population is often changing it. A dip that keeps going is a different situation and belongs with a clinician.
3. The prediction that cuts against it: uric acid should fall, magnesium should rise, and glucose should barely move in someone who is not hyperglycemic. Order uric acid, magnesium (serum) and HbA1c at baseline and 12 weeks. Urate falls because glucose in the tubule competes with urate at the GLUT9 exchanger — a genuine mechanistic bonus. Magnesium rises for reasons that are not fully explained. And HbA1c should be nearly unchanged in a person with a normal starting glucose, because the drug can only discard what is filtered. A metabolically healthy person taking this for longevity should expect the side effects at full strength and the glycemic effect at a fraction of it.
What nobody has tested yet
Four questions with no answer, and the first one is the whole longevity argument.
Nobody knows why the mouse lifespan effect is male-only. The pathology, the lifespan gain and the lesion protection were all concentrated in males Snyder 2023, and the commentary written about it says the mechanistic explanation remains unclear Wezeman 2022. Until that is understood, extrapolating the result to a female reader has no basis at all — and extrapolating it to a male human still crosses a species boundary.
Nobody has measured urinary glucose excretion in normoglycemic people on this drug. It is a 24-hour urine collection, it is inexpensive, and it would convert the caloric argument above from an estimate into a number. Every published excretion figure comes from populations with diabetes.
Nobody has tested intermittent dosing. The transporter effect outlasts the plasma curve, and the risks that scale with continuous glucosuria — mycotic infection, volume depletion — plausibly do not accumulate the same way on an intermittent schedule. Given that the geroprotective hypothesis is about long-term metabolic signaling rather than about day-to-day glucose control, this is an obvious question and it has not been asked.
Nobody has stratified response by UGT genotype in a healthy population. Glucuronidation carries the clearance, genetic variation in the relevant enzymes is documented Klen 2021, and modeling exists for renal impairment Guo 2025. What is missing is whether variation in exposure predicts either benefit or side effects in people taking it off-label.
Canagliflozin — its own safety story, not its class's
This drug has one hazard that is genuinely hard to detect, one that is common and mechanically obvious, and one that is a fluid problem. None of them is in a class block.
Euglycemic ketoacidosis is the dangerous one because the test everyone reaches for is normal. The mechanism is specific: glucosuria lowers plasma glucose and therefore insulin; low insulin permits lipolysis and hepatic ketogenesis; glucagon rises. Ketones accumulate while blood glucose stays in or near the normal range Lakusic 2022. A glucose meter cannot see it. The circumstances that provoke it are the ones people walk into deliberately: prolonged fasting, a ketogenic diet, heavy alcohol, acute illness, and the period around surgery. The instrument that detects it is a ketone meter, not a glucose meter, and it costs about the same. Persistent nausea, vomiting, abdominal pain or air hunger on this drug with a normal glucose is an emergency department situation rather than a wait-and-see one.
Genital mycotic infection is the common one, and it is not an idiosyncratic reaction — it is the mechanism. The drug's therapeutic effect is putting sugar into urine. Sugar in a warm moist environment grows yeast. This happens in a substantial minority, more in women, more in the uncircumcised, and it recurs while the drug continues. The rarer and far more serious version, necrotizing fasciitis of the perineum, is the reason that any genital pain, swelling or redness with fever on an SGLT2 inhibitor is urgent rather than embarrassing.
Volume depletion is the third, and it interacts with everything else in a longevity stack. Osmotic diuresis plus a diuretic, plus a low-carbohydrate diet, plus heat, plus deliberate fasting, is additive in one direction. Lightheadedness on standing is the early sign and it is worth taking seriously rather than pushing through, because volume depletion is also what turns a benign eGFR dip into an acute kidney injury.
And the amputation question, stated as it stands. CANVAS reported an imbalance in lower-limb amputations that was not reproduced in subsequent studies of the class, and the boxed warning that followed was later removed; the CANVAS and CREDENCE results are summarized together for exactly this kind of question Chen 2024 Sharma 2024. The honest position is that the signal was real in one trial, has not replicated, and that anyone with existing peripheral arterial disease or a foot ulcer is in the population where it was seen. This is a prescription medicine and none of this is medical advice.
Sources read for this page
- Sharma A, et al. Primary and Secondary Cardiovascular and Kidney Prevention With Canagliflozin: Insights From the CANVAS Program and CREDENCE Trial. Journal of the American Heart Association 2024 · PMID 38240199
- Chen AX, et al. An overview of the CANVAS Program and CREDENCE trial: The primary outcomes and key clinical implications for those managing patients with type 2 diabetes. Diabetes, Obesity and Metabolism 2024 · PMID 39036974
- Snyder JM, et al. Canagliflozin retards age-related lesions in heart, kidney, liver, and adrenal gland in genetically heterogenous male mice. GeroScience 2023 · PMID 35974129
- Wezeman J, et al. Sex Matters in Aging. The Canagliflozin Story. Aging Pathobiology and Therapeutics 2022 · PMID 36540066
- Lakusic N, et al. Euglycemic diabetic ketoacidosis: A rare but serious side effect of sodium-glucose co-transporter 2 inhibitors. World Journal of Cardiology 2022 · PMID 36339887
- Guo G, et al. Physiologically based pharmacokinetic model of sodium-glucose cotransporter 2 inhibitors predicted pharmacokinetics and pharmacodynamics to explore dosage regimen for patients with type 2 diabetes mellitus and renal insufficiency. Frontiers in Pharmacology 2025 · PMID 40230691
- Klen J, et al. Treatment Response to SGLT2 Inhibitors: From Clinical Characteristics to Genetic Variations. International Journal of Molecular Sciences 2021 · PMID 34575958
Canagliflozin — safety, from the human record
Not a prediction. This one has been studied in people. What follows is drawn from the human record — trials, labels and pharmacovigilance — rather than from what the mechanism implies. Where the way it is used here differs from what was studied, the card says so. How evidence is graded here →
What the mechanism predicts
Derived from the molecule, not a trial.
- Blocking the sodium-glucose cotransporter in the proximal tubule means glucose is excreted rather than reabsorbed. Three things follow directly: glucose in the urine (and therefore a genital and urinary environment that favors yeast), an osmotic diuresis with volume depletion and a small blood-pressure fall, and a shift toward fat oxidation and ketogenesis.
- That last one produces the class's signature emergency: euglycemic diabetic ketoacidosis — ketoacidosis with a glucose that looks normal or only mildly raised, which is exactly why it gets missed. The mechanism predicts it and it does not require diabetes to be severe.
What has actually been reported
- Genital mycotic infections are common and are the most frequent reason people stop.
- Euglycemic DKA is uncommon but well documented, and is precipitated by fasting, very low carbohydrate intake, alcohol, acute illness and surgery — every one of which is common in this audience.
- Volume depletion and orthostatic symptoms, particularly with a diuretic on board. An initial small creatinine rise that then stabilizes is expected.
- Genuine cardiovascular and renal outcome benefits across the class, largely independent of the glucose lowering — which is the reason for the longevity interest in the first place.
- Canagliflozin specifically carried an amputation signal in CANVAS that was not replicated in later programs; the boxed warning was subsequently removed. Worth knowing both halves of that story.
How to reduce the risk
Same mechanism as the prediction.
- Hold it during illness, fasting and before surgery — the sick-day rule is the single most important line on this card.
- Keep ketone strips and use them if you feel unwell, nauseated or breathless, whatever the glucose reads. Euglycemic DKA is missed because people check the wrong number.
- Drink to thirst and expect to urinate more; the diuresis is the mechanism.
- Genital hygiene reduces the mycotic infection rate, and an infection is treatable rather than a reason to abandon the class.
What it does to your bloodwork
A fact about the assay.
- Creatinine and electrolytes at baseline and after starting; the early dip is expected, a continuing rise is not.
- HbA1c — but note that glucose loss in the urine lowers HbA1c without changing anything about insulin sensitivity, so the number moving is not evidence the metabolism improved.
- Ketones, and know how to test them. This is the one measurement on this card that could matter urgently, and a glucose reading will not warn you.
What it overlaps with
- With loop or thiazide diuretics, the volume depletion adds. With insulin or a sulfonylurea, hypoglycemia risk adds.
Don't run this if
- Type 1 diabetes, outside specialist supervision.
- Any planned prolonged fast, ketogenic protocol or extended carbohydrate restriction without medical supervision — that is the euglycemic DKA setup.
- Recurrent genital or urinary infection.
- The days around surgery — guidance is to hold it beforehand.
The honest unknown
- Whether the cardiorenal benefit extends to metabolically healthy people. The outcome trials enrolled people with type 2 diabetes, heart failure or chronic kidney disease; taking it as a geroprotector in the absence of any of those is untested rather than disproven.
Not medical advice. If you take prescription medication or have a diagnosed condition, check this with a pharmacist or doctor.
Canagliflozin — interference & stacking
Predicted from mechanism, not from an interaction study. How mechanism-predicted claims are made →
What Canagliflozin moves on your bloodwork
Expected direction, not a measured one.
- TSH (Thyroid-Stimulating Hormone) — ↓ expected to fall
Exogenous thyroid hormone or a thyromimetic suppresses TSH by feedback. A suppressed TSH here is the expected consequence, not evidence of thyroid disease.
What to do: TSH alone is uninterpretable on these. Run free T3 and free T4 with it or the panel means nothing. - Free T3 (Triiodothyronine) — ↑ expected to rise
Rises with dosing, and this is the number driving both the benefit and the risk.
What to do: The gap between 'metabolically effective' and 'losing muscle and beating up your heart' is narrow. Test, don't estimate. - Complete Blood Count (CBC) with Differential — ◆ worth watching
Not the marker itself — but resting heart rate and blood pressure are the real-time readouts of over-dosing here, and they move before any lab does.
What to do: Take a resting heart rate every morning. It is a better early signal than a quarterly panel. - Comprehensive Metabolic Panel (CMP) — ◆ worth watching
Uncouplers and strong thermogenics raise metabolic demand and can stress liver enzymes.
What to do: Baseline liver function before, and again at 8 weeks.
- How to work up to it, and when not to
- When to take it, and why that window
- Cycle length
- Time off between cycles
- Fasted or fed, and when in the day
- Coach Cam's personal notes
- Which compounds push the same lever, and why the dose adds up faster than people count
- What blunts it — the stacks that waste your money
- What compounds the risk, so a side effect arrives sooner than any one of them suggests
- Coach Cam's read on running it alongside the rest of your protocol
Everything above is free and stays free. Skool is where it becomes a plan — Canagliflozin in an order, with the rest of what you're running.
Unlock in Skool — $10/mo →Bloodwork to run alongside Canagliflozin
Baseline first, then again at 8–12 weeks.
| Marker | What it’s watching for |
|---|---|
| hs-CRP (High-Sensitivity C-Reactive Protein) | Chronic low-grade inflammation is the process most of these target |
| ApoB (Apolipoprotein B) | Counts the particles that actually cause plaque, unlike LDL-C |
| HbA1c (Hemoglobin A1c) | Glycation, which is the other half of the ageing story |
| Comprehensive Metabolic Panel (CMP) | Liver and kidney — the two organs that clear everything you take |
| Complete Blood Count (CBC) with Differential | The cheapest broad screen there is |
The Longevity Baseline panel covers these in one order — 13 markers, $219.10 with the discount applied.
Check results you already have → · All 103 markers A–Z
Canagliflozin — frequently asked questions
What is Canagliflozin?
Canagliflozin (Invokana / SGLT2 inhibitor) is a longevity & bioregulators research compound. Blocks the sodium-glucose cotransporter in the proximal tubule so glucose is excreted in urine rather than reabsorbed. Beyond glucose, the class produces genuine cardiovascular and renal outcome benefits that appear largely independent of the glucose lowering.
Is the full Canagliflozin protocol on this page?
The reported research dose is on this page, along with how Canagliflozin works and the evidence behind it. The protocol — how to work up to it, frequency, cycle length, time off, what not to stack it with and Coach Cam's notes — is inside Skool.
What is the half-life of Canagliflozin?
Canagliflozin has an approximate half-life of ~11-13 hrs, which is part of what determines how often it's dosed.
What's the evidence behind Canagliflozin?
Current evidence level: Strong human outcome trials; rodent lifespan data (males). Canagliflozin is offered for research purposes only and is not an approved medicine.
Canagliflozin inside a finished plan
One arm of 1 Protocol Blueprint, free to read in full.
What Canagliflozin is used for
Canagliflozin appears under 3 goals in the goal router.
Related Longevity & Bioregulators compounds
Where this goes next
Canagliflozin is the post-meal arm of this plan. The page above is the free breakdown of one compound; the plan it belongs to — the dosing, the order to correct things in, the week-by-week schedule and what to retest — is a lesson inside Skool.